AK135 / Akesobio - LARVOL DELTA

Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025 (PRNewswire) - "In tumor cell models, AK135 significantly reduced the secretion of pro-inflammatory cytokines (such as IL-6 and IL-8) induced by IL-1, IL-33, and IL-36....Following AK135 treatment, the paw withdrawal threshold (PWT) in the CIPN model was significantly increased, indicating that AK135 effectively alleviated mechanical allodynia, with a dose-dependent efficacy."

Preclinical • Oncology • Pain

AK135, a novel antagonistic antibody targeting IL-1RAP for CIPN therapy (SITC 2025) - "A CIPN model in B6-hIL1RAP transgenic mice were established via intermittent low-dose paclitaxel induction. Then the pharmacological efficacy of AK135 in this model was evaluated.Results AK135 shows high affinity to IL-1RAP and exhibits potent neutralizing bioactivity in IL-1/IL-33/IL-36 signaling pathways, while Nadunolimab (CAN04) has a weaker blocking effect on the IL-33 and IL-36 signaling pathways, as shown in table 1...Additionally, AK135 treatment led to a dose-dependent decrease in pain-related cytokines in spinal cord tissue homogenates, supporting its anti-inflammatory mechanism in pain relief.Conclusions As a potential chemotherapy companion drug, AK135 potently targets IL-1RAP to block IL-1/IL-33/IL-36-driven inflammatory signaling, mitigates proinflammatory cytokine release, and alleviates chemotherapy-induced peripheral neuropathy (CIPN) in preclinical models. Its dose-dependent efficacy in pain relief, coupled with good tolerability, underscores..."

Oncology • CXCL8 • IL1RAP • IL33 • IL6